Holen Sie sich die Stockscreener-App
44.32
4.30%
-1.99
Vorhandelsmarkt:
44.42
0.10
+0.23%
Schlusskurs vom Vortag:
$46.31
Offen:
$46.27
24-Stunden-Volumen:
2.71M
Relative Volume:
1.13
Marktkapitalisierung:
$36.88B
Einnahmen:
$27.43B
Nettoeinkommen (Verlust:
$1.27B
KGV:
28.00
EPS:
1.5829
Netto-Cashflow:
$1.01B
1W Leistung:
+2.36%
1M Leistung:
+0.43%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$44.00
$46.90
1-Wochen-Bereich:
$43.41
$46.90
52-Wochen-Spanne:
$38.50
$46.90
Medline Inc Stock (MDLN) Company Profile
Vergleichen Sie MDLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDLN
Medline Inc
|
44.32 | 38.54B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ISRG
Intuitive Surgical Inc
|
522.04 | 186.12B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
201.92 | 57.95B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.42 | 39.72B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.72 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Medline Inc Stock (MDLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-21 | Bestätigt | BTIG Research | Buy |
| 2026-01-12 | Eingeleitet | Citigroup | Buy |
| 2026-01-12 | Eingeleitet | Deutsche Bank | Hold |
| 2026-01-12 | Eingeleitet | Evercore ISI | Outperform |
| 2026-01-12 | Eingeleitet | Goldman | Buy |
| 2026-01-12 | Eingeleitet | JP Morgan | Overweight |
| 2026-01-12 | Eingeleitet | Jefferies | Buy |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-01-12 | Eingeleitet | Mizuho | Outperform |
| 2026-01-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-01-12 | Eingeleitet | Piper Sandler | Overweight |
| 2026-01-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-12 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2026-01-12 | Eingeleitet | Stifel | Buy |
| 2026-01-12 | Eingeleitet | TD Cowen | Buy |
| 2026-01-12 | Eingeleitet | Truist | Buy |
| 2026-01-12 | Eingeleitet | UBS | Buy |
| 2026-01-12 | Eingeleitet | Wells Fargo | Equal Weight |
| 2026-01-12 | Eingeleitet | William Blair | Outperform |
| 2026-01-12 | Eingeleitet | Wolfe Research | Outperform |
Alle ansehen
Medline Inc Aktie (MDLN) Neueste Nachrichten
Medline to report fourth quarter and full year 2025 results on February 25, 2026 - GlobeNewswire
Is It Time To Reassess Medline (MDLN) After Its Recent Share Price Climb - Yahoo Finance
Medline Inc (MDLN) Shares Up 3.65% on Jan 22 - GuruFocus
Jim Cramer Says Medline "Stock Is Unbelievable" And Recommends Buying It - Finviz
Jim Cramer Says Medline “Stock Is Unbelievable” And Recommends Buying It - Yahoo Finance
Medline Industries: Solid Physical Moat With Visible Earnings Growth Runway (NASDAQ:MDLN) - Seeking Alpha
Jim Cramer Recently Looked at These 25 Stocks - Insider Monkey
Is There An Opportunity In Medline (MDLN) After Recent DCF Valuation Results - Sahm
Pointcore Supply Chain Services members select Medline as distributor - Medline Newsroom
Ranpak expands packaging automation partnership with Medline - Packaging Insights
In face of uncertainty and tariffs, newly public Medline sticks to the old formula - chicagobusiness.com
Ranpak in Collaboration with Medline - Medical Device and Diagnostic industry
Medline Shares Climb as Analysts Launch Coverage After $7.2 Bill - GuruFocus
Medline Shares Climb as Analysts Launch Coverage After $7.2 Billion IPO - Yahoo Finance
Ranpak and Medline Partner to for High-Volume Distribution Operations From: Ranpak Corporation - Healthcare Packaging
Ranpak Holdings Corp. and Medline Partner to Advance Automation and Sustainable Packaging Across High-Volume Distribution Operations - marketscreener.com
Ranpak and Medline Partner to Advance Automation and Sustainable Packaging Across High-Volume Distribution Operations - Business Wire
Analysts Are Bullish on These Healthcare Stocks: Exagen (XGN), Medline, Inc. Class A (MDLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Medline jumps as analysts bullish after 2025’s top IPO - The Daily Gazette
Medline Jumps as Analysts Bullish After 2025’s Top IPO - Bloomberg
Analysts initiate coverage on Medline after IPO, flag growth visibility and margin - Investing.com
Why Is Medline Stock Gaining Monday?Medline (NASDAQ:MDLN) - Benzinga
Analysts Say Medline Has The Secret Sauce For Sustained Growth - Sahm
Is Medline (MDLN) Fairly Priced After Recent Share Price Stability? - Yahoo Finance
Analysts initiate Medline with bullish ratings after blockbuster IPO - Reuters
TD Cowen initiates Medline stock with Buy rating on market share growth - Investing.com Nigeria
BTIG initiates coverage on Medline stock with Buy rating, $50 target By Investing.com - Investing.com South Africa
Wells Fargo & Company Begins Coverage on Medline (NASDAQ:MDLN) - MarketBeat
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Medline initiated with a Buy at BTIG - TipRanks
Goldman Sachs Initiates Coverage on Medline With Buy Rating, $49 Price Target - marketscreener.com
BMO Capital Initiates Coverage on Medline With Outperform Rating, $45 Price Target - marketscreener.com
JPMorgan Initiates Coverage on Medline With Overweight Rating, $50 Price Target - marketscreener.com
William Blair initiates Medline stock with Outperform rating By Investing.com - Investing.com South Africa
BTIG initiates coverage on Medline stock with Buy rating, $50 target - Investing.com Nigeria
Wells Fargo initiates coverage on Medline stock with Equal Weight rating - Investing.com Nigeria
BofA Securities initiates Medline stock with Buy rating, $50 price target - Investing.com Nigeria
Analysts initiate Medline with bullish ratings after blockbuster IPO By Reuters - Investing.com
Medline initiated with an Outperform at Mizuho - TipRanks
RBC Initiates Medline at Outperform With $47 Price Target - marketscreener.com
Medline (MDLN) Valuation Check As Shares Trade Near DCF Fair Value And Sector P/E Discount - Sahm
William Blair initiates Medline stock with Outperform rating - Investing.com
Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward - TipRanks
Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation - TipRanks
Medline: Prime Vendor Flywheel, Durable Growth, and Supportive Valuation Underscore Overweight/Buy Rating - TipRanks
Mizuho initiates Medline stock with Outperform rating, $48 price target By Investing.com - Investing.com India
Mizuho initiates Medline stock with Outperform rating, $48 price target - Investing.com
Analysts start coverage on Medline with bullish ratings - TradingView — Track All Markets
BMO Capital initiates Medline stock with Outperform rating, $45 target By Investing.com - Investing.com Nigeria
JPMorgan initiates Medline stock with Overweight rating, $50 price target By Investing.com - Investing.com Nigeria
Finanzdaten der Medline Inc-Aktie (MDLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):